Granted Patent
B2
US 11,352,412 · App. 16/189,917 · Granted Jun 7, 2022
CTLA4-IG immunoadhesins
Assignee:
Xencor, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
Claims (4)
1. An immunoadhesin comprising:
a first domain comprising a variant CTLA4 as compared to SEQ ID NO: 6, wherein said CTLA4 variant comprises amino acid substitutions A29H/T51N/L61E/K93Q; and
a second domain comprising an IgG Fc region.
2. The immunoadhesin of claim 1 , wherein said CTLA4 variant provides enhanced binding to B7-1, B7-2 or combination of B7-1 and B7-2.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 23, 2020
From: LAZAR, GREGORY A.; BERNETT, MATTHEW
To: XENCOR, INC.
Reel/Frame 052482/0202 →
Continuity (8)
Provisional Application
61412309
· Nov 10, 2010
Provisional Application
61334806
· May 14, 2010
Provisional Application
61306311
· Feb 19, 2010
Cited By (1)